These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27623022)

  • 21. Quinazoline derivatives as anticancer drugs: a patent review (2011 - present).
    Ravez S; Castillo-Aguilera O; Depreux P; Goossens L
    Expert Opin Ther Pat; 2015 Jul; 25(7):789-804. PubMed ID: 25910402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trabectedin: an anticancer drug from the sea.
    Ganjoo KN; Patel SR
    Expert Opin Pharmacother; 2009 Nov; 10(16):2735-43. PubMed ID: 19743937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trabectedin in soft tissue sarcomas.
    Brodowicz T
    Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trabectedin therapy for sarcomas.
    Casali PG; Sanfilippo R; D'Incalci M
    Curr Opin Oncol; 2010 Jul; 22(4):342-6. PubMed ID: 20489618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
    Simpson EL; Rafia R; Stevenson MD; Papaioannou D
    Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In brief: Two Drugs for soft-tissue sarcoma.
    Med Lett Drugs Ther; 2016 May; 58(1494):e62. PubMed ID: 27148925
    [No Abstract]   [Full Text] [Related]  

  • 27. What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience.
    Moriceau G; Vallard A; Méry B; Rivoirard R; Langrand-Escure J; Espenel S; Ben Mrad M; Wang G; Diao P; Fournel P; Collard O; Magné N
    Bull Cancer; 2015 Oct; 102(10):814-22. PubMed ID: 26384694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sigma receptor modulators: a patent review.
    Collina S; Gaggeri R; Marra A; Bassi A; Negrinotti S; Negri F; Rossi D
    Expert Opin Ther Pat; 2013 May; 23(5):597-613. PubMed ID: 23387851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ET-743: a novel agent with activity in soft-tissue sarcomas.
    Fayette J; Coquard IR; Alberti L; Boyle H; Méeus P; Decouvelaere AV; Thiesse P; Sunyach MP; Ranchère D; Blay JY
    Curr Opin Oncol; 2006 Jul; 18(4):347-53. PubMed ID: 16721129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
    Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Trabectedin registry].
    Kubácková K; Fínek J; Vyzula R; Zvaríková M; Vocka M; Batko S; Dreslerová J; Lazarov PP; Lysý M; Ptátková Z; Benesová V; Bortlícek Z; Kandrnal V
    Klin Onkol; 2011; 24(6):470-4. PubMed ID: 22257238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
    Le Cesne A; Cresta S; Maki RG; Blay JY; Verweij J; Poveda A; Casali PG; Balaña C; Schöffski P; Grosso F; Lardelli P; Nieto A; Alfaro V; Demetri GD
    Eur J Cancer; 2012 Nov; 48(16):3036-44. PubMed ID: 22749255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report.
    Bongiovanni A; Riva N; Ricci M; Mercatali L; Liverani C; La Manna F; De Vita A; Cavaliere D; Pieri F; Oboldi D; Verdecchia GM; Amadori D; Ibrahim T
    BMC Cancer; 2015 Dec; 15():998. PubMed ID: 26695071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biology of ovarian cancer and trabectedin mechanism of action.
    Ray-Coquard I
    Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
    Grosso F; Jones RL; Demetri GD; Judson IR; Blay JY; Le Cesne A; Sanfilippo R; Casieri P; Collini P; Dileo P; Spreafico C; Stacchiotti S; Tamborini E; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Fletcher JA; Pilotti S; Casali PG
    Lancet Oncol; 2007 Jul; 8(7):595-602. PubMed ID: 17586092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.
    Sanfilippo R; Grosso F; Jones RL; Banerjee S; Pilotti S; D'Incalci M; Dei Tos AP; Raspagliesi F; Judson I; Casali PG
    Gynecol Oncol; 2011 Dec; 123(3):553-6. PubMed ID: 21917307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
    Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
    Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trabectedin--a targeted chemotherapy?
    von Mehren M
    Lancet Oncol; 2007 Jul; 8(7):565-7. PubMed ID: 17613417
    [No Abstract]   [Full Text] [Related]  

  • 39. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
    Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
    Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Going further in the knowledge of Yondelis®; what's new in daily clinical practice?
    Blay JY
    Future Oncol; 2014 Jun; 10(8 Suppl):s13-7. PubMed ID: 25048044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.